Journal of the American Heart Association · 2025
Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baik Minyoul, Jeon Jimin, Yoo Joonsang, Kim Jinkwon
Аннотация
BACKGROUND: Guidelines for lipid-lowering therapy in patients with dialysis-dependent chronic kidney disease remain ambiguous. We aimed to explore cardiovascular outcomes associated with statin use in patients with hemodialysis-dependent chronic kidney disease, stratified by prior statin use.
METHODS: This was a retrospective cohort study of patients with chronic kidney disease who initiated maintenance hemodialysis, using a nationwide health claims database in Korea between 2010 and 2021. A multivariate Cox regression analysis was performed, incorporating statin use throughout the follow-up period as a time-dependent variable. The primary outcome was a composite of stroke, myocardial infarction, and all-cause mortality. A subgroup analysis was conducted based on statin use before hemodialysis initiation.
RESULTS: Of the 49 868 study participants, the mean age at hemodialysis initiation was 65.5±11.2 years, and 32 225 (64.6%) were men. During a mean follow-up of 3.8 years, the primary composite outcome occurred in 20 345 patients (40.8%). Throughout the follow-up period, approximately 40% of patients received statin therapy. Statin use was significantly associated with a reduced risk of the primary composite outcome (adjusted hazard ratio, 0.51 [95% CI, 0.49-0.53]; P<0.001). This association was consistent regardless of prior statin use, although the benefit was less pronounced in statin-naïve patients (P for interaction <0.001).
CONCLUSIONS: Statin use was consistently associated with improved long-term cardiovascular outcomes in patients with hemodialysis-dependent chronic kidney disease, regardless of prior statin use. These findings suggest that continuing statin therapy is crucial for cardiovascular prevention in patients already receiving statins before hemodialysis initiation; initiating statin therapy may also provide clinical benefits in statin-naïve patients undergoing hemodialysis.
METHODS: This was a retrospective cohort study of patients with chronic kidney disease who initiated maintenance hemodialysis, using a nationwide health claims database in Korea between 2010 and 2021. A multivariate Cox regression analysis was performed, incorporating statin use throughout the follow-up period as a time-dependent variable. The primary outcome was a composite of stroke, myocardial infarction, and all-cause mortality. A subgroup analysis was conducted based on statin use before hemodialysis initiation.
RESULTS: Of the 49 868 study participants, the mean age at hemodialysis initiation was 65.5±11.2 years, and 32 225 (64.6%) were men. During a mean follow-up of 3.8 years, the primary composite outcome occurred in 20 345 patients (40.8%). Throughout the follow-up period, approximately 40% of patients received statin therapy. Statin use was significantly associated with a reduced risk of the primary composite outcome (adjusted hazard ratio, 0.51 [95% CI, 0.49-0.53]; P<0.001). This association was consistent regardless of prior statin use, although the benefit was less pronounced in statin-naïve patients (P for interaction <0.001).
CONCLUSIONS: Statin use was consistently associated with improved long-term cardiovascular outcomes in patients with hemodialysis-dependent chronic kidney disease, regardless of prior statin use. These findings suggest that continuing statin therapy is crucial for cardiovascular prevention in patients already receiving statins before hemodialysis initiation; initiating statin therapy may also provide clinical benefits in statin-naïve patients undergoing hemodialysis.